The DOI matches its Crossref record; 18 of the 18 references it cites were found in a registry or an index; 4 of the 10 sources its claims cite were checked for support.
Idecabtagene Vicleucel in Relapsed and Refractory Multiple Myeloma.
Open accessAbstract
BACKGROUND: Idecabtagene vicleucel (ide-cel, also called bb2121), a B-cell maturation antigen-directed chimeric antigen receptor (CAR) T-cell therapy, has shown clinical activity with expected CAR T-cell toxic effects in patients with relapsed and refractory multiple myeloma. METHODS: CAR-positive (CAR+) T cells. The primary end point was an overall response (partial response or better); a key secondary end point was a complete response or better (comprising complete and stringent complete responses). RESULTS: nucleated cells) was confirmed in 33 patients, representing 26% of all 128 patients who were treated and 79% of the 42 patients who had a complete response or better. The median progression-free survival was 8.8 months (95% confidence interval, 5.6 to 11.6). Common toxic effects among the 128 treated patients included neutropenia in 117 patients (91%), anemia in 89 (70%), and thrombocytopenia in 81 (63%). Cytokine release syndrome was reported in 107 patients (84%), including 7 (5%) who had events of grade 3 or higher. Neurotoxic effects developed in 23 patients (18%) and were of grade 3 in 4 patients (3%); no neurotoxic effects higher than grade 3 occurred. Cellular kinetic analysis confirmed CAR+ T cells in 29 of 49 patients (59%) at 6 months and 4 of 11 patients (36%) at 12 months after infusion. CONCLUSIONS: Ide-cel induced responses in a majority of heavily pretreated patients with refractory and relapsed myeloma; MRD-negative status was achieved in 26% of treated patients. Almost all patients had grade 3 or 4 toxic effects, most commonly hematologic toxic effects and cytokine release syndrome. (Funded by bluebird bio and Celgene, a Bristol-Myers Squibb company; KarMMa ClinicalTrials.gov number, NCT03361748.).
Overview
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
4 of 10 cited sources checked · 2 supported · 0 flagged · accuracy not yet measured
Every source the paper cites for this claim was checked and supports it.
In the paper
“The B-cell maturation antigen (BCMA)-directed CAR T cell idecabtagene vicleucel (ide-cel, also called bb2121) showed promising efficacy in a phase 1 study involving patients with relapsed or refractory myeloma.11”
§ Idecabtagene Vicleucel in Relapsed and Refractory Multiple Myeloma > D
What the sources say
- Supportedcites [11] 11. Raje N, Berdeja J, Lin Y, et al. Anti- BCMA CAR T-cell therapy bb2121 in re- lapsed or refractory multiple myeloma. N Engl J Med 2019; 380: 1726-37. source
The Methods identify bb2121 as an anti-BCMA CAR T-cell therapy studied in a phase 1 trial involving patients with relapsed or refractory multiple myeloma. The Discussion reports an 85% clinical response rate, supporting the characterization of its efficacy as promising. (LLM, conf=0.94)
Tests✓ Asserted: passes✓ Checkable: passes✓ Load-bearing: passes✓ Based: passes- Supported
The sources with a verdict support this claim; the rest weren’t checked yet, have no full text we could read, or their verdicts aren’t rated yet.
In the paper
“These efficacy results compare favorably with results in similarly heavily pretreated patients with relapsed or refractory myeloma treated with two recently approved regimens, selinexor plus dexamethasone and belantamab mafodotin (median progression-free survival, 3.7 months and 2.9 months, respectively).5,17”
§ Idecabtagene Vicleucel in Relapsed and Refractory Multiple Myeloma > Discussion
What the sources say
- Supportedcites [5] 5. Chari A, Vogl DT, Gavriatopoulou M, et al. Oral selinexor-dexamethasone for triple-class refractory multiple myeloma. N Engl J Med 2019; 381: 727-38. source
The Methods and Discussion describe patients with triple-class refractory myeloma who were heavily pretreated, with a median of seven previous regimens. The Efficacy section reports median progression-free survival of 3.7 months with selinexor plus dexamethasone. This citation supports the selinexor result; the separate belantamab result is not attributed to this paper. (LLM, conf=0.92)
- Not checked — no full text of the sourcecites [17] 17. Lonial S, Lee HC, Badros A, et al. Belan- tamab mafodotin for relapsed or refracto- ry multiple myeloma (DREAMM-2): a two- arm, randomised, open-label, phase 2 study. Lancet Oncol 2020; 21: 207-21. source
Load-bearingStrength:plain· not yet calibratedTests✓ Asserted: passes✓ Checkable: passes✓ Load-bearing: passes✓ Based: passes- Rests on an assumption: Cross-trial comparisons of progression-free survival between the KarMMa study and trials of selinexor plus dexamethasone or belantamab mafodotin are valid.
- Supported
The cited sources support only part of this claim — read each source’s verdict below.
In the paper
“Observed toxic effects were consistent with those in previous reports.11”
§ Idecabtagene Vicleucel in Relapsed and Refractory Multiple Myeloma > Discussion
What the sources say
- Partly supportedcites [11] 11. Raje N, Berdeja J, Lin Y, et al. Anti- BCMA CAR T-cell therapy bb2121 in re- lapsed or refractory multiple myeloma. N Engl J Med 2019; 380: 1726-37. sourceExperimental — accuracy not yet measured
The Results (Safety; page unavailable) document the observed toxic effects. The Discussion compares them with previous studies, but reports a lower incidence of severe cytokine release syndrome with bb2121 and cautions that cross-study comparisons are complicated. It does not establish that the toxic effects were generally consistent with previous reports. (LLM, conf=0.82)
Strength:plain· not yet calibratedTests✓ Asserted: passes✓ Checkable: passes? Load-bearing: unclear✓ Based: passes- Partly supported
A result the paper reports from its own data — it cites no other source for it, so there is none to check. The quote shows it is in the paper.
In the paper
“Duration of undetectable sBCMA correlated with response duration, and clearance of sBCMA at month 2 was associated with longer progression-free survival (Fig. S5E and S5F).”
§ Idecabtagene Vicleucel in Relapsed and Refractory Multiple Myeloma > Figure 2 (facing page). Progression-free Survival, Duration of Response, and Overall Survival.
Strength:plain· not yet calibratedCausal:correlational· not yet calibratedTests✓ Asserted: passes✓ Checkable: passes? Load-bearing: unclear✓ Based: passes- Rests on an assumption: Soluble BCMA is a serum-based universal marker of myeloma burden.
A result the paper reports from its own data — it cites no other source for it, so there is none to check. The quote shows it is in the paper.
In the paper
“with peak levels higher in patients having cytokine release syndrome of grade 3 or higher (Fig. S6).”
§ Idecabtagene Vicleucel in Relapsed and Refractory Multiple Myeloma > Biomarkers
Strength:plain· not yet calibratedCausal:correlational· not yet calibratedTests✓ Asserted: passes✓ Checkable: passes? Load-bearing: unclear✓ Based: passesA result the paper reports from its own data — it cites no other source for it, so there is none to check. The quote shows it is in the paper.
In the paper
“a somewhat higher frequency and somewhat greater depth of response were observed at the 450 × 10 6 dose (response in 81% of the pa-tients and complete response or better in 39%).”
§ Idecabtagene Vicleucel in Relapsed and Refractory Multiple Myeloma > Discussion
Strength:plain· not yet calibratedTests✓ Asserted: passes✓ Checkable: passes? Load-bearing: unclear✓ Based: passesA result the paper reports from its own data — it cites no other source for it, so there is none to check. The quote shows it is in the paper.
In the paper
“At baseline, 110 of 112 tumor samples (98%) expressed BCMA, with 109 having at least 50% BCMA-positive plasma cells, and all the patients had detectable levels of sBCMA.”
§ Idecabtagene Vicleucel in Relapsed and Refractory Multiple Myeloma > Figure 2 (facing page). Progression-free Survival, Duration of Response, and Overall Survival.
Strength:plain· not yet calibratedn = 112Tests✓ Asserted: passes✓ Checkable: passes? Load-bearing: unclear✓ Based: passesA result the paper reports from its own data — it cites no other source for it, so there is none to check. The quote shows it is in the paper.
In the paper
“A response was observed in 73% of the treated patients, and a complete response or better was observed in 33%;”
§ Idecabtagene Vicleucel in Relapsed and Refractory Multiple Myeloma > Discussion
Load-bearingStrength:plain· not yet calibratedTests✓ Asserted: passes✓ Checkable: passes✓ Load-bearing: passes✓ Based: passesA result the paper reports from its own data — it cites no other source for it, so there is none to check. The quote shows it is in the paper.
In the paper
“Baseline cytokine levels were not associated with higher-grade cytokine release syndrome or neurotoxic effects.”
§ Idecabtagene Vicleucel in Relapsed and Refractory Multiple Myeloma > Biomarkers
Strength:plain· not yet calibratedTests✓ Asserted: passes✓ Checkable: passes? Load-bearing: unclear✓ Based: passesA result the paper reports from its own data — it cites no other source for it, so there is none to check. The quote shows it is in the paper.
In the paper
“with an incidence of response to bridging therapy of 4%”
§ Idecabtagene Vicleucel in Relapsed and Refractory Multiple Myeloma > Discussion
Strength:plain· not yet calibratedTests✓ Asserted: passes✓ Checkable: passes? Load-bearing: unclear✓ Based: passes
- Probably not a substantial claim. 12
- It may state two separate claims as one. 32
- The quote only partly states this claim. 1
The cited sources support only part of this claim — read each source’s verdict below.
In the paper
“In contrast, CD19 epitope loss is reported to be a relatively common escape mechanism after treatment with CD19-directed CAR T-cell therapy, especially in patients with acute leukemia.18,19”
§ Idecabtagene Vicleucel in Relapsed and Refractory Multiple Myeloma > Discussion
What the sources say
- Partly supportedcites [18] 18. Cheng J, Zhao L, Zhang Y, et al. Un- derstanding the mechanisms of resis- tance to CAR T-cell therapy in malignan- cies. Front Oncol 2019; 9: 1237. sourceExperimental — accuracy not yet measured
The Tumor Factors section reports that loss of the targeted CD19 epitope enabled escape after anti-CD19 CAR T-cell therapy in relapsed B-ALL. It also reports that target-antigen-negative relapse accounts for approximately 9–25% of B-ALL relapses, but does not establish that epitope loss specifically is relatively common or more common in acute leukemia than in other malignancies. (LLM, conf=0.82)
- Not checked — no full text of the sourcecites [19] 19. Badar T, Shah NN. Chimeric antigen receptor T cell therapy for acute lympho- blastic leukemia. Curr Treat Options On- col 2020; 21: 16. source
Strength:plain· not yet calibratedCausal:direct· not yet calibratedTests✓ Asserted: passes✓ Checkable: passes✗ Load-bearing: fails✓ Based: passesProbably not a substantial claim. The paper’s conclusions may not depend on it.
- Partly supported
A result the paper reports from its own data — it cites no other source for it, so there is none to check. The quote shows it is in the paper.
In the paper
“Among patients with persistent grade 3 or 4 neutropenia (52 patients) or thrombocytopenia (62 patients) 1 month after infusion, the median time to recovery to grade 2 or lower was 1.9 months (range, 1.2 to 5.6) and 2.1 months (range, 1.2 to 13.8), respectively”
§ Idecabtagene Vicleucel in Relapsed and Refractory Multiple Myeloma > Safety
Strength:plain· not yet calibratedn = 52Tests✓ Asserted: passes✓ Checkable: passes? Load-bearing: unclear✓ Based: passesIt may state two separate claims as one.
A result the paper reports from its own data — it cites no other source for it, so there is none to check. The quote shows it is in the paper.
In the paper
“The Kaplan-Meier estimated median progression-free survival was 8.8 months overall (95% CI, 5.6 to 11.6), 12.1 months (95% CI, 8.8 to 12.3) at the 450 × 10 6 dose, and 20.2 months (95% CI, 12.3 to could not be estimated) in patients having a complete or stringent complete response”
§ Idecabtagene Vicleucel in Relapsed and Refractory Multiple Myeloma > Efficacy
Load-bearingStrength:hedged· not yet calibratedTests✓ Asserted: passes✓ Checkable: passes✓ Load-bearing: passes✓ Based: passesIt may state two separate claims as one.
A result the paper reports from its own data — it cites no other source for it, so there is none to check. The quote shows it is in the paper.
In the paper
“The 128 treated patients had received a median of 6 previous antimyeloma regimens (range, 3 to 16), and 120 (94%) had received previous autologous hematopoietic stem-cell transplants (Table 1).”
§ Idecabtagene Vicleucel in Relapsed and Refractory Multiple Myeloma > Patients
Strength:plain· not yet calibratedn = 128Tests✓ Asserted: passes✓ Checkable: passes? Load-bearing: unclear✓ Based: passesIt may state two separate claims as one.
A result the paper reports from its own data — it cites no other source for it, so there is none to check. The quote shows it is in the paper.
In the paper
“Although high interpatient variability was observed at all doses, upper quartiles of exposure (area under the curve of the transgene level from time of dose to 28 days [AUC 0-28 days ]) were observed more frequently at the 450 × 10 6 dose (Fig. 3B).”
§ Idecabtagene Vicleucel in Relapsed and Refractory Multiple Myeloma > Cellular Pharmacokinetic Profile and Immunogenicity
Tests✓ Asserted: passes✓ Checkable: passes? Load-bearing: unclear✓ Based: passesIt may state two separate claims as one.
A result the paper reports from its own data — it cites no other source for it, so there is none to check. The quote shows it is in the paper.
In the paper
“Among treated patients, 5 were positive for antidrug antibodies before infusion.”
§ Idecabtagene Vicleucel in Relapsed and Refractory Multiple Myeloma > Cellular Pharmacokinetic Profile and Immunogenicity
Strength:plain· not yet calibratedTests✓ Asserted: passes✓ Checkable: passes✗ Load-bearing: fails✓ Based: passesProbably not a substantial claim. The paper’s conclusions may not depend on it.
A result the paper reports from its own data — it cites no other source for it, so there is none to check. The quote shows it is in the paper.
In the paper
“Baseline sBCMA levels were elevated in treated patients and de-creased rapidly after infusion in patients who had a response, with nadir values achieved within 3 months (Fig. 3A and Fig. S5B and S5C).”
§ Idecabtagene Vicleucel in Relapsed and Refractory Multiple Myeloma > Biomarkers
Strength:plain· not yet calibratedCausal:correlational· not yet calibratedTests✓ Asserted: passes✓ Checkable: passes? Load-bearing: unclear✓ Based: passesIt may state two separate claims as one.
- Rests on an assumption: Soluble BCMA is a serum-based universal marker of myeloma burden.
A result the paper reports from its own data — it cites no other source for it, so there is none to check. The quote shows it is in the paper.
In the paper
“Neurotoxic effects developed in 23 patients (18%) and were of grade 3 in 4 patients (3%); no neurotoxic effects higher than grade 3 occurred.”
- Also stated in: § Table 1. (Continued.) · plain
“Investigator-identified neurotoxic effects were reported in 23 patients (18%), of whom 4 (3%) had grade 3 events; no grade 4 or 5 neu-rotoxic effects were observed”
§ Idecabtagene Vicleucel in Relapsed and Refractory Multiple Myeloma > Abstract
Strength:plain· not yet calibratedn = 128Tests✓ Asserted: passes✓ Checkable: passes? Load-bearing: unclear✓ Based: passesIt may state two separate claims as one.
- Also stated in: § Table 1. (Continued.) · plain
A result the paper reports from its own data — it cites no other source for it, so there is none to check. The quote shows it is in the paper.
In the paper
“The median time to first response was 1.0 month (range, 0.5 to 8.8); the median time to a complete response or better was 2.8 months (range, 1.0 to 11.8).”
§ Idecabtagene Vicleucel in Relapsed and Refractory Multiple Myeloma > Efficacy
Strength:plain· not yet calibratedTests✓ Asserted: passes✓ Checkable: passes? Load-bearing: unclear✓ Based: passesIt may state two separate claims as one.
A result the paper reports from its own data — it cites no other source for it, so there is none to check. The quote shows it is in the paper.
In the paper
“At doses of 150 × 10 6 , 300 × 10 6 , and 450 × 10 6 CAR+ T cells, neurotoxic effects of any grade were reported in 0 of 4 patients, 12 of 70 patients (17%), and 11 of 54 patients (20%), respectively, with grade 3 events in 0 patients, 1 patient (1%), and 3 patients (6%).”
§ Idecabtagene Vicleucel in Relapsed and Refractory Multiple Myeloma > Table 1. (Continued.)
Strength:plain· not yet calibratedn = 54Tests✓ Asserted: passes✓ Checkable: passes? Load-bearing: unclear✓ Based: passesIt may state two separate claims as one.
A result the paper reports from its own data — it cites no other source for it, so there is none to check. The quote shows it is in the paper.
In the paper
“Antidrug antibodies had no effect on the incidence of response or of complete response or better and had no noticeable effect on progression-free survival.”
§ Idecabtagene Vicleucel in Relapsed and Refractory Multiple Myeloma > Cellular Pharmacokinetic Profile and Immunogenicity
Strength:plain· not yet calibratedTests✓ Asserted: passes✓ Checkable: passes? Load-bearing: unclear✓ Based: passesIt may state two separate claims as one.
- Rests on an assumption: The absence of a detectable effect of antidrug antibodies on efficacy is not due to insufficient statistical power.
A result the paper reports from its own data — it cites no other source for it, so there is none to check. The quote shows it is in the paper.
In the paper
“The Kaplan-Meier estimated median overall survival was 19.4 months (95% CI, 18.2 to could not be estimated), with an overall survival of 78% at 12 months (Fig. 2D).”
§ Idecabtagene Vicleucel in Relapsed and Refractory Multiple Myeloma > Efficacy
Load-bearingStrength:hedged· not yet calibratedTests✓ Asserted: passes✓ Checkable: passes✓ Load-bearing: passes✓ Based: passesIt may state two separate claims as one.
A result the paper reports from its own data — it cites no other source for it, so there is none to check. The quote shows it is in the paper.
In the paper
“Exposures were higher in patients who had a response than in those who did not (Fig. S5A), and higher exposure was associated with deeper response and longer progression-free survival (Fig. 3C and 3D).”
§ Idecabtagene Vicleucel in Relapsed and Refractory Multiple Myeloma > Cellular Pharmacokinetic Profile and Immunogenicity
Tests✓ Asserted: passes✓ Checkable: passes? Load-bearing: unclear✓ Based: passesIt may state two separate claims as one.
A result the paper reports from its own data — it cites no other source for it, so there is none to check. The quote shows it is in the paper.
In the paper
“Achievement of undetectable sBCMA levels increased with depth of response (17 of 27 pa-”
§ Idecabtagene Vicleucel in Relapsed and Refractory Multiple Myeloma > Biomarkers
Strength:plain· not yet calibratedCausal:correlational· not yet calibratedTests✓ Asserted: passes✓ Checkable: passes? Load-bearing: unclear✓ Based: passesThe quote only partly states this claim.
- Rests on an assumption: Soluble BCMA is a serum-based universal marker of myeloma burden.
A result the paper reports from its own data — it cites no other source for it, so there is none to check. The quote shows it is in the paper.
In the paper
“At doses of 150 × 10 6 , 300 × 10 6 , and 450 × 10 6 CAR+ T cells, cytokine release syndrome of any grade was observed in 2 of 4 patients (50%), 53 of 70 patients (76%), and 52 of 54 patients (96%), respectively, with cytokine release syndrome of grade 3 or higher observed in 0 patients, 4 patients (6%), and 3 patients (6%).”
§ Idecabtagene Vicleucel in Relapsed and Refractory Multiple Myeloma > Table 1. (Continued.)
Tests✓ Asserted: passes✓ Checkable: passes? Load-bearing: unclear✓ Based: passesIt may state two separate claims as one.
A result the paper reports from its own data — it cites no other source for it, so there is none to check. The quote shows it is in the paper.
In the paper
“The Kaplan-Meier estimate for median duration of response was 10.7 months (95% CI, 9.0 to 11.3) overall and 11.3 months (95% CI, 10.3 to 11.4) at the 450 × 10 6 dose”
§ Idecabtagene Vicleucel in Relapsed and Refractory Multiple Myeloma > Efficacy
Load-bearingStrength:hedged· not yet calibratedTests✓ Asserted: passes✓ Checkable: passes✓ Load-bearing: passes✓ Based: passesIt may state two separate claims as one.
A result the paper reports from its own data — it cites no other source for it, so there is none to check. The quote shows it is in the paper.
In the paper
“Cytokine release syndrome was reported in 107 patients (84%), including 7 (5%) who had events of grade 3 or higher.”
- Also stated in: § Table 1. (Continued.) · plain
“Cytokine release syndrome occurred in 107 patients (84%) and was mostly of grade 1 or 2 (Table 2 and Table S10).Five patients (4%) had grade 3 cytokine release syndrome, 1 (<1%) had grade 4, and 1 (<1%) had grade 5 (300 × 10 6 dose level).”
§ Idecabtagene Vicleucel in Relapsed and Refractory Multiple Myeloma > Abstract
Strength:plain· not yet calibratedn = 128Tests✓ Asserted: passes✓ Checkable: passes? Load-bearing: unclear✓ Based: passesIt may state two separate claims as one.
- Also stated in: § Table 1. (Continued.) · plain
A result the paper reports from its own data — it cites no other source for it, so there is none to check. The quote shows it is in the paper.
In the paper
“Infections occurred in 88 patients (69%) and were of grade 3 or 4 in 28 (22%).”
§ Idecabtagene Vicleucel in Relapsed and Refractory Multiple Myeloma > Safety
Strength:plain· not yet calibratedn = 88Tests✓ Asserted: passes✓ Checkable: passes? Load-bearing: unclear✓ Based: passesIt may state two separate claims as one.
A result the paper reports from its own data — it cites no other source for it, so there is none to check. The quote shows it is in the paper.
In the paper
“including many with a high tumor burden, high-risk cytogenetic abnormalities, and extramedullary disease.”
§ Idecabtagene Vicleucel in Relapsed and Refractory Multiple Myeloma > Discussion
Strength:plain· not yet calibratedTests✓ Asserted: passes✓ Checkable: passes? Load-bearing: unclear✓ Based: passesIt may state two separate claims as one.
A result the paper reports from its own data — it cites no other source for it, so there is none to check. The quote shows it is in the paper.
In the paper
“Common toxic effects among the 128 treated patients included neutropenia in 117 patients (91%), anemia in 89 (70%), and thrombocytopenia in 81 (63%).”
§ Idecabtagene Vicleucel in Relapsed and Refractory Multiple Myeloma > Abstract
Strength:plain· not yet calibratedn = 128Tests✓ Asserted: passes✓ Checkable: passes? Load-bearing: unclear✓ Based: passesIt may state two separate claims as one.
A result the paper reports from its own data — it cites no other source for it, so there is none to check. The quote shows it is in the paper.
In the paper
“After disease progression, 28 patients were retreated with ide-cel (Table S4).Six patients (21%) had a second response, with durations of response ranging from 1.9 to 6.8 months; all the patients who had a response were retreated at a dose higher than their initial dose.”
§ Idecabtagene Vicleucel in Relapsed and Refractory Multiple Myeloma > Efficacy
Tests✓ Asserted: passes✓ Checkable: passes? Load-bearing: unclear✓ Based: passesIt may state two separate claims as one.
A result the paper reports from its own data — it cites no other source for it, so there is none to check. The quote shows it is in the paper.
In the paper
“Most grade 3 or 4 events were hematologic toxic effects, including neutropenia in 114 patients (89%), anemia in 77 (60%), and thrombocytopenia in 67 (52%), and were at least partially related to the lymphodepleting chemotherapy administered before ide-cel infusion.”
§ Idecabtagene Vicleucel in Relapsed and Refractory Multiple Myeloma > Safety
Strength:plain· not yet calibratedn = 114Tests✓ Asserted: passes✓ Checkable: passes? Load-bearing: unclear✓ Based: passesIt may state two separate claims as one.
A result the paper reports from its own data — it cites no other source for it, so there is none to check. The quote shows it is in the paper.
In the paper
“A total of 44 treated patients (34%) died during the study, with most deaths (27) attributed by the investigator to complications of myeloma progression (Table S12).”
§ Idecabtagene Vicleucel in Relapsed and Refractory Multiple Myeloma > Table 1. (Continued.)
Strength:plain· not yet calibratedn = 44Tests✓ Asserted: passes✓ Checkable: passes? Load-bearing: unclear✓ Based: passesIt may state two separate claims as one.
A result the paper reports from its own data — it cites no other source for it, so there is none to check. The quote shows it is in the paper.
In the paper
“Levels of proinflammatory markers, including cytokines, ferritin, and C-reactive protein, increased early after ide-cel infusion and decreased by month 1”
§ Idecabtagene Vicleucel in Relapsed and Refractory Multiple Myeloma > Biomarkers
Strength:plain· not yet calibratedCausal:direct· not yet calibratedTests✓ Asserted: passes✓ Checkable: passes? Load-bearing: unclear✓ Based: passesIt may state two separate claims as one.
A result the paper reports from its own data — it cites no other source for it, so there is none to check. The quote shows it is in the paper.
In the paper
“The response duration increased with the depth of response; the median response duration was 4.5 months (95% CI, 2.9 to 6.7), 10.4 months (95% CI, 5.1 to 11.3), and 19.0 months (95% CI, 11.3 to could not be estimated) in patients having a best response of partial response (27 patients), very good partial response (25 patients), and complete or stringent complete response (42 patients),”
§ Idecabtagene Vicleucel in Relapsed and Refractory Multiple Myeloma > Efficacy
Strength:plain· not yet calibratedCausal:correlational· not yet calibratedTests✓ Asserted: passes✓ Checkable: passes? Load-bearing: unclear✓ Based: passesIt may state two separate claims as one.
A result the paper reports from its own data — it cites no other source for it, so there is none to check. The quote shows it is in the paper.
In the paper
“At the target doses of 150 × 10 6 , 300 × 10 6 , and 450 × 10 6 CAR+ T cells, a response was observed in 2 of 4 patients (50%), in 48 of 70 patients (69%), and in 44 of 54 patients (81%), respectively, and a complete response or better was observed in 1 of 4 patients (25%), in 20 of 70 patients (29%), and in 21 of 54 patients (39%).”
§ Idecabtagene Vicleucel in Relapsed and Refractory Multiple Myeloma > Efficacy
Tests✓ Asserted: passes✓ Checkable: passes✓ Load-bearing: passes✓ Based: passesIt may state two separate claims as one.
A result the paper reports from its own data — it cites no other source for it, so there is none to check. The quote shows it is in the paper.
In the paper
“Five patients (4%) died after 6 months from unrelated adverse events, and an additional 8 patients (6%) died after disease progression.”
§ Idecabtagene Vicleucel in Relapsed and Refractory Multiple Myeloma > Table 1. (Continued.)
Strength:plain· not yet calibratedn = 5Tests✓ Asserted: passes✓ Checkable: passes? Load-bearing: unclear✓ Based: passesIt may state two separate claims as one.
A result the paper reports from its own data — it cites no other source for it, so there is none to check. The quote shows it is in the paper.
In the paper
“Minimal residual disease (MRD)-negative status (<10 -5 nucleated cells) was confirmed in 33 patients, representing 26% of all 128 patients who were treated and 79% of the 42 patients who had a complete response or better.”
- Also stated in: § Efficacy · plain
“Of the 42 patients with a complete or stringent complete response, 33 (79%) also had MRDnegative status at a sensitivity level of 10 -5 , corresponding to 26% (95% CI, 19 to 34) of the treated population; the remaining 9 patients (21%) could not be evaluated for MRD”
§ Idecabtagene Vicleucel in Relapsed and Refractory Multiple Myeloma > Abstract
Strength:plain· not yet calibratedn = 33Tests✓ Asserted: passes✓ Checkable: passes? Load-bearing: unclear✓ Based: passesIt may state two separate claims as one.
- Also stated in: § Efficacy · plain
The paper states this without a source or data behind it here, so there is nothing to check it against. The quote shows it is in the paper.
In the paper
“High-grade hematologic toxic effects were common but transient.”
§ Idecabtagene Vicleucel in Relapsed and Refractory Multiple Myeloma > Discussion
Strength:plain· not yet calibratedTests✓ Asserted: passes✓ Checkable: passes? Load-bearing: unclear✓ Based: passesIt may state two separate claims as one.
A conclusion the paper draws from its own results — it cites no other source for it, so there is none to check. The quote shows it is in the paper.
In the paper
“The fact that MRDnegative responses occurred in approximately a quarter of the patients highlights the depth of response induced by ide-cel.”
§ Idecabtagene Vicleucel in Relapsed and Refractory Multiple Myeloma > Discussion
Tests✓ Asserted: passes✓ Checkable: passes✓ Load-bearing: passes✓ Based: passesIt may state two separate claims as one.
- Rests on an assumption: MRD negativity at a sensitivity of 10^-5 is a valid measure of depth of response and clinical benefit.
What the paper did — it cites no source for this, so there is none to check. The quote shows it is in the paper.
In the paper
“The study protocol was approved by local or independent institutional review boards or ethics committees at participating sites.All the patients provided written informed consent.”
§ Idecabtagene Vicleucel in Relapsed and Refractory Multiple Myeloma > Study Oversight
Strength:plain· not yet calibratedTests✓ Asserted: passes✓ Checkable: passes✗ Load-bearing: fails✓ Based: passesProbably not a substantial claim. The paper’s conclusions may not depend on it. It may state two separate claims as one.
A conclusion the paper draws from its own results — it cites no other source for it, so there is none to check. The quote shows it is in the paper.
In the paper
“Nearly all tumors expressed BCMA, a finding that supports the use of ide-cel in relapsed and refractory myeloma without restriction based on tumor BCMA expression.”
§ Idecabtagene Vicleucel in Relapsed and Refractory Multiple Myeloma > Discussion
Tests✓ Asserted: passes✓ Checkable: passes✓ Load-bearing: passes✓ Based: passesIt may state two separate claims as one.
- Rests on an assumption: BCMA expression is required for ide-cel efficacy, so lack of tumor BCMA expression would limit its use.
What the paper did — it cites no source for this, so there is none to check. The quote shows it is in the paper.
In the paper
“The primary efficacy analysis was performed in the population of patients treated with ide-cel (128 patients).”
§ Idecabtagene Vicleucel in Relapsed and Refractory Multiple Myeloma > Statistical Analysis
Tests✓ Asserted: passes✓ Checkable: passes✓ Load-bearing: passes✓ Based: passesProbably not a substantial claim.
What the paper did — it cites no source for this, so there is none to check. The quote shows it is in the paper.
In the paper
“Between December 13, 2017, and November 13, 2018, a total of 140 patients were enrolled and underwent leukapheresis, of whom 128 received ide-cel infusions.Twelve patients discontinued the study before ide-cel infusion (including 1 patient who discontinued after unsuccessful manufacture of the CAR T-cell product)”
§ Idecabtagene Vicleucel in Relapsed and Refractory Multiple Myeloma > Patients
Strength:plain· not yet calibratedn = 140Tests✓ Asserted: passes✓ Checkable: passes✗ Load-bearing: fails✓ Based: passesProbably not a substantial claim. The paper’s conclusions may not depend on it. It may state two separate claims as one.
What the paper did — it cites no source for this, so there is none to check. The quote shows it is in the paper.
In the paper
“The study was designed by the authors in conjunction with the sponsors and conducted in accordance with the International Council for Harmonisation guidelines for Good Clinical Practice and the principles of the Declaration of Helsinki.”
§ Idecabtagene Vicleucel in Relapsed and Refractory Multiple Myeloma > Study Oversight
Strength:plain· not yet calibratedTests✓ Asserted: passes✓ Checkable: passes✗ Load-bearing: fails✓ Based: passesProbably not a substantial claim. The paper’s conclusions may not depend on it. It may state two separate claims as one.
What the paper did — it cites no source for this, so there is none to check. The quote shows it is in the paper.
In the paper
“The sample size for the primary end point (overall response) was based on a onesample binomial test with normal approximation, under the assumption of 15% dropout between the time of enrollment and ide-cel treatment.”
§ Idecabtagene Vicleucel in Relapsed and Refractory Multiple Myeloma > Statistical Analysis
Tests✓ Asserted: passes✓ Checkable: passes✓ Load-bearing: passes✓ Based: passesProbably not a substantial claim.
What the paper did — it cites no source for this, so there is none to check. The quote shows it is in the paper.
In the paper
“Statistical tests were not performed on subgroup analyses.”
§ Idecabtagene Vicleucel in Relapsed and Refractory Multiple Myeloma > Statistical Analysis
Strength:plain· not yet calibratedTests✓ Asserted: passes✓ Checkable: passes✗ Load-bearing: fails✓ Based: passesProbably not a substantial claim. The paper’s conclusions may not depend on it.
What the paper did — it cites no source for this, so there is none to check. The quote shows it is in the paper.
In the paper
“The primary end point was an overall response (partial response or better), defined according to IMWG Uniform Response Criteria for Multiple Myeloma 12 as assessed by an independent review committee.”
§ Idecabtagene Vicleucel in Relapsed and Refractory Multiple Myeloma > End Points and Assessments
Load-bearingStrength:plain· not yet calibratedTests✓ Asserted: passes✓ Checkable: passes✓ Load-bearing: passes✓ Based: passesProbably not a substantial claim.
What the paper did — it cites no source for this, so there is none to check. The quote shows it is in the paper.
In the paper
“MRD negativity was evaluated in bone marrow aspirates by next-generation sequencing (clonoSEQ, Adaptive Biotechnologies) with a minimum cutoff of 10 -5 nucleated cells.”
§ Idecabtagene Vicleucel in Relapsed and Refractory Multiple Myeloma > End Points and Assessments
Load-bearingStrength:plain· not yet calibratedTests✓ Asserted: passes✓ Checkable: passes✓ Load-bearing: passes✓ Based: passesProbably not a substantial claim.
What the paper did — it cites no source for this, so there is none to check. The quote shows it is in the paper.
In the paper
“The actual doses delivered were within 20% of the target doses.”
§ Idecabtagene Vicleucel in Relapsed and Refractory Multiple Myeloma > Study Design and Patients
Strength:plain· not yet calibratedTests✓ Asserted: passes✓ Checkable: passes✗ Load-bearing: fails✓ Based: passesProbably not a substantial claim. The paper’s conclusions may not depend on it.
What the paper did — it cites no source for this, so there is none to check. The quote shows it is in the paper.
In the paper
“Adverse events were graded according to National Cancer Institute Common Terminology Criteria for Adverse Events (NCI CTCAE), version 4.03.Cytokine release syndrome was graded according to published criteria (Table S2).14”
§ Idecabtagene Vicleucel in Relapsed and Refractory Multiple Myeloma > End Points and Assessments
Strength:plain· not yet calibratedTests✓ Asserted: passes✓ Checkable: passes✗ Load-bearing: fails✓ Based: passesProbably not a substantial claim. The paper’s conclusions may not depend on it. It may state two separate claims as one.
The paper relies on this without support.
Soluble BCMA is a serum-based universal marker of myeloma burden.
“Soluble BCMA was assessed as a serum-based universal marker of myeloma burden.”
The paper relies on this without support.
Cross-trial comparisons of progression-free survival between the KarMMa study and trials of selinexor plus dexamethasone or belantamab mafodotin are valid.
“These efficacy results compare favorably with results in similarly heavily pretreated patients with relapsed or refractory myeloma treated with two recently approved regimens, selinexor plus dexamethasone and belantamab mafodotin (median progression-free survival, 3.7 months and 2.9 months, respectively).5,17”
The paper relies on this without support.
MRD negativity at a sensitivity of 10^-5 is a valid measure of depth of response and clinical benefit.
“The fact that MRDnegative responses occurred in approximately a quarter of the patients highlights the depth of response induced by ide-cel.”
The paper relies on this without support.
BCMA expression is required for ide-cel efficacy, so lack of tumor BCMA expression would limit its use.
“Nearly all tumors expressed BCMA, a finding that supports the use of ide-cel in relapsed and refractory myeloma without restriction based on tumor BCMA expression.”
The paper relies on this without support.
The absence of a detectable effect of antidrug antibodies on efficacy is not due to insufficient statistical power.
“Antidrug antibodies had no effect on the incidence of response or of complete response or better and had no noticeable effect on progression-free survival.”
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
The source backs part of the claim, not all of it — or backs it for a different population, condition or comparison.
In the citing paper
“Idecabtagene vicleucel (ide-cel) and ciltacabtagene autoleucel (cilta-cel) are newly approved CAR-T products targeting BCMA that are active in relapsed refractory myeloma.89,90”
From Multiple myeloma: 2024 update on diagnosis, risk-stratification, and management (2024) · cites this paper as [89]
Experimental — accuracy not yet measuredThe source backs part of the claim, not all of it — or backs it for a different population, condition or comparison.
In the citing paper
“Safety of ide-cel remained consistent with the IA, with no parkinsonism, Guillain-Barré syndrome, or SPMs of T-cell origin reported. 13”
From Ide-cel vs standard regimens in triple-class-exposed relapsed and refractory multiple myeloma: updated KarMMa-3 analyses. (2024) · cites this paper as [18]
Experimental — accuracy not yet measuredThe source backs part of the claim, not all of it — or backs it for a different population, condition or comparison.
In the citing paper
“Common side effects such as CRS and immune effector cell-associated neurotoxicity syndrome (ICANS) were mostly low grade, indicating manageable toxicity.”
From Multiple myeloma: signaling pathways and targeted therapy (2024) · cites this paper as [243]
Experimental — accuracy not yet measuredThe source backs part of the claim, not all of it — or backs it for a different population, condition or comparison.
In the citing paper
“The median duration of response (mDOR) was 11 months in patients achieving CR and 19 months in those achieving stringent complete response (sCR).”
From Multiple myeloma: signaling pathways and targeted therapy (2024) · cites this paper as [243]
Experimental — accuracy not yet measuredThe source backs part of the claim, not all of it — or backs it for a different population, condition or comparison.
In the citing paper
“A number of BCMA-directed therapies, including belantamab mafodotin, idecabtagene vicleucel (ide-cel), ciltacabtagene autoleucel (cilta-cel) and teclistamab, have shown efficacy in clinical trials and are approved for the treatment of relapsed or refractory multiple myeloma4–9.”
From Elranatamab in relapsed or refractory multiple myeloma: phase 2 MagnetisMM-3 trial results (2023) · cites this paper as [5]
Experimental — accuracy not yet measured
The source backs part of the claim, not all of it — or backs it for a different population, condition or comparison.
In the citing paper
“Median DOR and PFS were 10.7 months and 8.8 months, respectively, for ide-cel, and were both not reached for cilta-cel5,6.”
From Elranatamab in relapsed or refractory multiple myeloma: phase 2 MagnetisMM-3 trial results (2023) · cites this paper as [5]
Experimental — accuracy not yet measuredThe source backs part of the claim, not all of it — or backs it for a different population, condition or comparison.
In the citing paper
“Although follow-up is still ongoing, among patients with ≥CR, DOR and PFS at 15 months with elranatamab were comparable to those observed with other BCMA-targeted T-cell-redirecting therapies, suggesting similar outcomes once a deep response is achieved5,24,25.”
From Elranatamab in relapsed or refractory multiple myeloma: phase 2 MagnetisMM-3 trial results (2023) · cites this paper as [5]
Experimental — accuracy not yet measuredThe source backs part of the claim, not all of it — or backs it for a different population, condition or comparison.
In the citing paper
“High response rates have been reported with the BCMA chimeric antigen receptor (CAR) T-cell therapies, ide-cel and cilta-cel, with responses reported in 73% and 97% of treated patients, respectively.”
From Elranatamab in relapsed or refractory multiple myeloma: phase 2 MagnetisMM-3 trial results (2023) · cites this paper as [5]
Experimental — accuracy not yet measuredThe source backs part of the claim, not all of it — or backs it for a different population, condition or comparison.
In the citing paper
“In comparison to other BCMA-targeted T-cell-redirecting therapies, the rate of hematologic AEs with elranatamab was similar or lower after a similar follow-up4–6.”
From Elranatamab in relapsed or refractory multiple myeloma: phase 2 MagnetisMM-3 trial results (2023) · cites this paper as [5]
Experimental — accuracy not yet measuredThe source backs part of the claim, not all of it — or backs it for a different population, condition or comparison.
In the citing paper
“CAR-T therapy requires that patients have access to specialized care centers and can wait the minimum 4-week period for production, which can result in attrition rates of approximately 10 to 15%,6-8”
From Teclistamab in Relapsed or Refractory Multiple Myeloma (2022) · cites this paper as [6]
Experimental — accuracy not yet measuredThe cited source says what the claim attributes to it.
In the citing paper
“Among 128 patients with relapsed refractory myeloma treated on a phase II trial, ide-cel was associated with a response rate of 73%.89 Thirty three percent of patients had a complete response or better. The median PFS was 8.8 months.”
From Multiple myeloma: 2024 update on diagnosis, risk-stratification, and management (2024) · cites this paper as [89]
The cited source says what the claim attributes to it.
In the citing paper
“Cytokine release syndrome was seen in 84%, and 5% were grade 3 or higher. Neurotoxicity was seen in 18%, and was grade 3 in 3%.”
From Multiple myeloma: 2024 update on diagnosis, risk-stratification, and management (2024) · cites this paper as [89]
The cited source says what the claim attributes to it.
In the citing paper
“Chimeric antigen receptor (CAR) T-cell therapy has shown promising ef fi cacy in patients with TCE R/RMM. 13-21”
From Ide-cel vs standard regimens in triple-class-exposed relapsed and refractory multiple myeloma: updated KarMMa-3 analyses. (2024) · cites this paper as [18]
The cited source says what the claim attributes to it.
In the citing paper
“In the KarMMa study involving 128 patients with RRMM, the overall response rate (ORR) to a single infusion of Abecma was 73%, with a complete response (CR) rate of 33%.”
From Multiple myeloma: signaling pathways and targeted therapy (2024) · cites this paper as [243]
The cited source says what the claim attributes to it.
In the citing paper
“Abecma has demonstrated the ability to induce rapid, deep, and long-lasting remissions with just one infusion, providing a new and effective personalized therapy option for MM patients [227, 243, 258, 259].”
From Multiple myeloma: signaling pathways and targeted therapy (2024) · cites this paper as [243]
The cited source says what the claim attributes to it.
In the citing paper
“In contrast, higher-grade cytokine release syndrome and neurotoxic events have been described after CAR-T administration in patients with multiple myeloma.6,8”
From Teclistamab in Relapsed or Refractory Multiple Myeloma (2022) · cites this paper as [6]
The check wasn’t confident either way, so it gives no verdict — never disputed.
In the citing paper
“Similarly, patients with advanced disease stage (R-ISS stage III) have consistently shown poorer outcomes irrespective of the therapy received4–6,19–22.”
From Elranatamab in relapsed or refractory multiple myeloma: phase 2 MagnetisMM-3 trial results (2023) · cites this paper as [5]
Experimental — accuracy not yet measuredIn the citing paper
“Recently approved therapies such as selinexor, 9 belantamab mafodotin, 10 idecabtagene vicleucel, 11 and ciltacabtagene autoleucel 12 have had clinical benefit in patients with relapsed or refractory multiple myeloma.”
From Talquetamab, a T-Cell–Redirecting GPRC5D Bispecific Antibody for Multiple Myeloma (2022) · cites this paper as [11]
Citations
Cites
Kumar, S., Paiva, B., Anderson, K. C., Durie, B., Landgren, O., Moreau, P., Munshi, N., Lonial, S., Bladé, J., Mateos, M.-V., et al. (2016) · The Lancet Oncology · doi:10.1016/s1470-2045(16)30206-6 · Cited by 3,061
Self-citationCurrent concepts in the diagnosis and management of cytokine release syndrome.
Lee, D. W., Gardner, R., Porter, D. L., Louis, C. U., Ahmed, N., Jensen, M., Grupp, S. A., & Mackall, C. L. (2014) · Blood · doi:10.1182/blood-2014-05-552729 · Cited by 2,806
Anti-BCMA CAR T-cell therapy bb2121 in relapsed or refractory multiple myeloma.
Raje, N., Berdeja, J., Lin, Y., Siegel, D., Jagannath, S., Madduri, D., Liedtke, M., Rosenblatt, J., Maus, M. V., Turka, A., et al. (2019) · New England Journal of Medicine · doi:10.1056/nejmoa1817226 · Cited by 1,730
Self-citationLonial, S., Lee, H. C., Badros, A., Trudel, S., Nooka, A. K., Chari, A., Abdallah, A.-O., Callander, N., Lendvai, N., Sborov, D., et al. (2020) · The Lancet Oncology · doi:10.1016/s1470-2045(19)30788-0 · Cited by 812
Self-citationOral selinexor-dexamethasone for triple-class refractory multiple myeloma.
Chari, A., Vogl, D. T., Gavriatopoulou, M., Nooka, A. K., Yee, A. J., Huff, C. A., Moreau, P., Dingli, D., Cole, C., Lonial, S., et al. (2019) · New England Journal of Medicine · doi:10.1056/nejmoa1903455 · Cited by 666
Self-citationOutcomes of patients with multiple myeloma refractory to CD38-targeted monoclonal antibody therapy.
Gandhi, U. H., Cornell, R. F., Lakshman, A., Gahvari, Z. J., McGehee, E., Jagosky, M. H., Gupta, R., Varnado, W., Fiala, M. A., Chhabra, S., et al. (2019) · Leukemia · doi:10.1038/s41375-019-0435-7 · Cited by 616
Friedman, K. M., Garrett, T. E., Evans, J. W., Horton, H. M., Latimer, H. J., Seidel, S. L., Horvath, C. J., & Morgan, R. A. (2018) · Human Gene Therapy · doi:10.1089/hum.2018.001 · Cited by 205
Treatment of relapsed and refractory multiple myeloma
Sonneveld, P., & Broijl, A. (2016) · Haematologica · doi:10.3324/haematol.2015.129189 · Cited by 181
CAR T-cell therapy in hematologic malignancies: a voyage in progress.
Holstein, S. A., & Lunning, M. A. (2020) · Clinical Pharmacology & Therapeutics · doi:10.1002/cpt.1674 · Cited by 172
Understanding the mechanisms of resistance to CAR T-cell therapy in malignancies.
Cheng, J., Zhao, L., Zhang, Y., Qin, Y., Guan, Y., Zhang, T., Liu, C., & Zhou, J. (2019) · Frontiers in Oncology · doi:10.3389/fonc.2019.01237 · Cited by 153
Flagged first, then by citations
Cited by
Sorted by citations
Items 401–500 of 2,535
Ellithi, M., Elsallab, M., Lunning, M., Holstein, S., Sharma, S., Trinh, J., Ma, J.-Y., Maus, M. V., Frigault, M., & D'Angelo, C. R. (2024) · Transplantation and Cellular Therapy · doi:10.1016/j.jtct.2024.12.002 · Cited by 41
Zhao, G., Wei, R., Feng, L., Wu, Y., He, F., Xiao, M., & Zhi, C. (2021) · Cancer Immunology Immunotherapy · doi:10.1007/s00262-021-02959-8 · Cited by 38
Next-Generation Implementation of Chimeric Antigen Receptor T-Cell Therapy Using Digital Health
Banerjee, R. K., Shah, N. D., & Dicker, A. P. (2021) · JCO Clinical Cancer Informatics · doi:10.1200/cci.21.00023 · Cited by 38
Self-citationKfir‐Erenfeld, S., Asherie, N., Grisariu, S., et al. (2022) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-22-0637 · Cited by 38
Novel BCMA-OR-CD38 tandem-dual chimeric antigen receptor T cells robustly control multiple myeloma
Feng, Y., Liu, X., Li, X., Zhou, Y., Song, Z., Zhang, J., Shi, B., & Wang, J. (2021) · OncoImmunology · doi:10.1080/2162402x.2021.1959102 · Cited by 35
Immune dysregulation in multiple myeloma: the current and future role of cell-based immunotherapy
Russell, B., & Avigan, D. (2023) · International journal of hematology · doi:10.1007/s12185-023-03579-x · Cited by 36
“Cytopenias were commonly observed with nearly 22% experiencing grade 3–4 infectious complications likely related to the effects of lymphodepletion as well as post-CAR immune modulation [73].”
BackgroundPaiva, B., Manrique, I., Rytlewski, J. A., Campbell, T., Kazanecki, C. C., Martin, N., Anderson, L. D., Berdeja, J. G., Lonial, S., Raje, N. S., et al. (2023) · Blood Cancer Discovery · doi:10.1158/2643-3230.bcd-23-0044 · Cited by 36
“MRD was analyzed at months 1, 3, 6, and 12 within the first year after ide-cel infusion regardless of clinical response.”
MethodSelf-citationBeyond youth: Understanding CAR T cell fitness in the context of immunological aging
Noll, J. H., Levine, B. L., June, C. H., & Fraietta, J. A. (2023) · Seminars in Immunology · doi:10.1016/j.smim.2023.101840 · Cited by 41
Brudno, J. N., Natrakul, D. A., Karrs, J. X., Patel, N., Maass‐Moreno, R., Ahlman, M. A., Mikkilineni, L., Mann, J., Stroncek, D. F., Highfill, S. L., et al. (2023) · Blood Advances · doi:10.1182/bloodadvances.2023011470 · Cited by 40
Addressing the disparities: the approach to the African American patient with multiple myeloma
Bhutani, M., Blue, B. J., Cole, C. E., Badros, A. Z., Usmani, S. Z., Nooka, A. K., Bernal‐Mizrachi, L., & Mikhael, J. R. (2023) · Blood Cancer Journal · doi:10.1038/s41408-023-00961-0 · Cited by 38
Reyes, K., Liu, Y.-C., Huang, C.-Y., Banerjee, R., Martin, T., Wong, S. W., Wolf, J., Arora, S., Shah, N., Chari, A., et al. (2024) · Blood Advances · doi:10.1182/bloodadvances.2023012066 · Cited by 37
Self-citationHuang, Y., Qin, Y., He, Y., Qiu, D., Zheng, Y., Wei, J., Zhang, L., Yang, D., & Li, Y. (2024) · Drug Resistance Updates · doi:10.1016/j.drup.2024.101082 · Cited by 40
The potential and promise for clinical application of adoptive T cell therapy in cancer
Li, Y., Zheng, Y., Liu, T., Liao, C., Shen, G., & He, Z. (2024) · Journal of Translational Medicine · doi:10.1186/s12967-024-05206-7 · Cited by 41
“In the KarMMa trial (NCT03361748), patients with R/R MM who had undergone at least three prior treatments were administrated Idecabtagene vicleucel target doses ranging from 150 × 10 6 to 450 × 10 6 CAR T cells [114].”
BackgroundMethodTherapeutic advances in the targeting of ROR1 in hematological cancers
Tigu, A.-B., Munteanu, R. A., Moldovan, C. S., Drulă, R., Kegyes, D., Tomai, R. A., Moisoiu, V., Ghiaur, G., Tomuleasa, C., Einsele, H., et al. (2024) · Cell Death Discovery · doi:10.1038/s41420-024-02239-1 · Cited by 39
Self-citationBraun, T., Rade, M., Merz, M., Klepzig, H., Große, F., Fandrei, D., Pham, N.-N., Kreuz, M., Kuhn, C. K., Kuschel, F., et al. (2025) · Nature Medicine · doi:10.1038/s41591-025-03499-9 · Cited by 47
CAR-engineered lymphocyte persistence is governed by a FAS ligand–FAS autoregulatory circuit
Yi, F., Cohen, T., Zimmerman, N., Dündar, F., Zumbo, P., Eltilib, R., Brophy, E. J., Arkin, H., Feucht, J., Gormally, M. V., et al. (2025) · Nature Cancer · doi:10.1038/s43018-025-01009-x · Cited by 55
“Beginning the day of NK cell transfer, an extended half-life variant of interleukin (IL)-15 was administered by intraperitoneal (i.p.) injection to model the physiologic effect of lymphodepletion 44 .”
Palomba, M. L., Qualls, D. A., Monette, S., Sethi, S., Doǧan, A., Roshal, M., Sénéchal, B., Wang, X., Rivière, I., Sadelain, M., et al. (2022) · Journal for ImmunoTherapy of Cancer · doi:10.1136/jitc-2021-004128 · Cited by 37
Donor T cells for CAR T cell therapy
Tang, T. C. Y., Xu, N., Nordon, R. E., Haber, M., Micklethwaite, K. P., & Dolnikov, A. (2022) · Biomarker Research · doi:10.1186/s40364-022-00359-3 · Cited by 43
“The FDA has also approved idecabtagene vicleucel (Abecma, Bristol Myers Squibb), an autologous antiBCMA CAR T cell therapy, for treating adult r/r MM [7, 29].”
BackgroundDhodapkar, M. V. (2022) · American Journal of Hematology · doi:10.1002/ajh.26752 · Cited by 41
“Early expansion of CARTs in vivo correlates with initial response to these therapies.(99,100) Recent application of highdimensional profiling has shown that BCMA CAR-T therapy also leads to major alterations in endogenous T cells.”
BackgroundLiu, Y., Jie, X., Li, N., Wang, Y., Wang, C., Ma, J., Jiang, J., Wu, Q., Qiao, J., Chen, W., et al. (2023) · Frontiers in Immunology · doi:10.3389/fimmu.2023.1169071 · Cited by 36
“However, there was significant discrepancy in respect to longterm outcomes, and some patients experienced early progression or relapse (3, 4).”
BackgroundEngelhardt, M. M., Kortüm, K. M., Goldschmidt, H., & Merz, M. (2024) · Haematologica · doi:10.3324/haematol.2023.283058 · Cited by 50
Self-citationChallenges and strategies associated with CAR-T cell therapy in blood malignancies
Liu, Z., Lei, W., Wang, H., Liu, X., & Fu, R. (2024) · Experimental Hematology and Oncology · doi:10.1186/s40164-024-00490-x · Cited by 43
“Clinical trials assessing the efficacy of these cells have shown significant remissions during treatment of refractory MM and improvements in the patient quality of life scores [74–76].”
BackgroundSaldarriaga, M. M., Pan, D., Unkenholz, C., Mouhieddine, T. H., Velez-Hernandez, J. E., Engles, K., Fein, J. A., Monge, J., Rosenbaum, C. A., Pearse, R. N., et al. (2024) · Blood Advances · doi:10.1182/bloodadvances.2023012470 · Cited by 36
Neri, P., Leblay, N., Lee, H., Gullà, A., Bahlis, N. J., & Anderson, K. C. (2024) · Nature Reviews Clinical Oncology · doi:10.1038/s41571-024-00913-y · Cited by 38
“Patients with a CR/sCR had a median PFS of 20.2 months 38 .”
InfluentialTreatment outcomes of triple class refractory multiple myeloma: a benchmark for new therapies
Bal, S., Malek, E., Kansagra, A. J., Usmani, S. Z., Vij, R., Godby, K. N., Cornell, R. F., Kang, Y., Umyarova, E. R., Giri, S., et al. (2021) · Leukemia · doi:10.1038/s41375-021-01471-3 · Cited by 36
“B cell maturation (BCMA) directed chimeric antigen receptor T cell therapies appears to hold the most potential to alter the natural history of TCR MM based on response rates exceeding 80% at target dose levels and relatively durable remission with a one-time treatment [5, 6].”
BackgroundTh17.1 cell driven sarcoidosis-like inflammation after anti-BCMA CAR T cells in multiple myeloma
Leipold, A. M., Werner, R. A., Düll, J., Jung, P., John, M., Stanojkovska, E., Zhou, X., Hornburger, H., Ruckdeschel, A. M., Dietrich, O., et al. (2023) · Leukemia · doi:10.1038/s41375-023-01824-0 · Cited by 35
Self-citationBücklein, V., Perez, A. P., Rejeski, K., Iacoboni, G., Jurinović, V., Holtick, U., Penack, O., Kharboutli, S., Blumenberg, V., Ackermann, J., et al. (2023) · HemaSphere · doi:10.1097/hs9.0000000000000907 · Cited by 36
Reynolds, G. K., Sim, B., Spelman, T. D., Thomas, A., Longhitano, A., Anderson, M. A., Thursky, K., Slavin, M. A., & Teh, B. W. (2023) · Critical Reviews in Oncology/Hematology · doi:10.1016/j.critrevonc.2023.104134 · Cited by 36
Banerjee, R., Cicero, K. I., Lee, S. S., & Cowan, A. J. (2023) · Frontiers in Oncology · doi:10.3389/fonc.2023.1240966 · Cited by 33
“Kumar et al (16) 494 ≤12 months of ASCT 24% 27 (23-31) 91 (71-111)”
ResultGenetic Basis of Relapse after GPRC5D-Targeted CAR T Cells
Mi, X., Penson, A., Abdel-Wahab, O. I., & Mailankody, S. (2023) · New England Journal of Medicine · doi:10.1056/nejmc2308544 · Cited by 38
Degagné, É., Donohoue, P. D., Roy, S., Scherer, J., Fowler, T. W., Davis, R. T., Reyes, G. A., Kwong, G., Stanaway, M., Vicena, V. L., et al. (2024) · Cancer Immunology Research · doi:10.1158/2326-6066.cir-23-0679 · Cited by 35
“…fi ctargetingofmultiplemyeloma cells, functionally addressing both allograft rejection by the host lymphoid compartment and GvHD. BCMA targeting with autologous CAR T cell therapies has demonstrated a substantial impact on disease progression in relapsed/refractory multiple myeloma (26, 27, 39).”
Haderbache, R., Warda, W., Hervouet, É., Rocha, M. N. D., Trad, R., Allain, V., Nicod, C., Thieblemeont, C., Boissel, N., Varlet, P., et al. (2021) · Journal of Translational Medicine · doi:10.1186/s12967-021-02925-z · Cited by 37
“Consequently, treatment of refractory/relapsed (R/R) acute lymphoblastic leukemia (ALL) [2], diffuse large B cell lymphoma (DLBCL), and chronic lymphoid leukemia (CLL) [3] patients has led to approval, by US and EU regulatory agencies, of four autologous CAR T drugs directed against CD19 (tisagenlecleucel/tisa-cel/ Ky…”
BackgroundSelf-citationExpanding anti-CD38 immunotherapy for lymphoid malignancies
Wang, X., Yu, X., Li, W., Neeli, P. K., Liu, M., Li, L., Zhang, M., Fang, X., Young, K. H., & Li, Y. (2022) · Journal of Experimental & Clinical Cancer Research · doi:10.1186/s13046-022-02421-2 · Cited by 36
Treatment horizon in multiple myeloma
Soekojo, C. Y., & Chng, W. J. (2022) · European Journal Of Haematology · doi:10.1111/ejh.13840 · Cited by 37
“Cytokine release syndrome was reported in 84% of patients, with around 5% having grade 3 effect.(124) The FDA has approved ide-cel for the treatment of adult patients with MM who have received at least four prior therapies, including an IMiD, a PI, and an anti-CD38 antibody.”
BackgroundShahzad, M., Nguyen, A., Hussain, A., Ammad-Ud-Din, M., Faisal, M. S., Tariq, E. F., Ali, F., Butt, A., Anwar, I., Chaudhary, S. G., et al. (2023) · Frontiers in Immunology · doi:10.3389/fimmu.2023.1152457 · Cited by 35
“The median age of patients was 41 (7-80) years (13–25).”
BackgroundMetelo, A. M., Jóźwik, A., Luong, L. A., Dominey-Foy, D., Graham, C., Attwood, C., Inam, S., Dunlop, A. S., Sanchez, K., Cuthill, K., et al. (2022) · Cancer Research Communications · doi:10.1158/2767-9764.crc-21-0157 · Cited by 35
García‐Guerrero, E., Rodríguez‐Lobato, L. G., Sierro-Martínez, B., Danhof, S., Bates, S., Frenz, S., Härtle, L., Götz, R., Sauer, M., Rasche, L., et al. (2022) · Haematologica · doi:10.3324/haematol.2022.281339 · Cited by 35
“6 In the Cartitude-1 study, Ciltacabtagene autoleucel has achieved an ORR of 97%, and the mean PFS had not been reached at 24 months.”
Self-citationHashmi, H., Hansen, D. K., Peres, L. C., Puglianini, O., Freeman, C. L., Avila, G. D., Sidana, S., Shune, L., Sborov, D., Davis, J. A., et al. (2023) · Haematologica · doi:10.3324/haematol.2023.283888 · Cited by 40
Self-citationLiang, X.-J., Wang, Y.-F., Luo, B.-W., Lin, B., Lu, W.-X., Tian, S., Liu, D., & Wang, L. (2024) · Journal for ImmunoTherapy of Cancer · doi:10.1136/jitc-2024-010064 · Cited by 38
Strategies to Overcome Failures in T-Cell Immunotherapies by Targeting PI3K-δ and –γ
Chandrasekaran, S., Funk, C. R., Kleber, T. J., Paulos, C. M., Shanmugam, M., & Waller, E. K. (2021) · Frontiers in Immunology · doi:10.3389/fimmu.2021.718621 · Cited by 36
Kittel-Boselli, E., Soto, K. E. G., Loureiro, L. R., Hoffmann, A., Bergmann, R., Arndt, C., Koristka, S., Mitwasi, N., Kegler, A., Bartsch, T., et al. (2021) · Cancers · doi:10.3390/cancers13194785 · Cited by 35
Nanomaterials to improve cancer immunotherapy based on ex vivo engineered T cells and NK cells
Han, B., Song, Y., Park, J., & Doh, J. (2022) · Journal of Controlled Release · doi:10.1016/j.jconrel.2022.01.049 · Cited by 33
Hematologic cytopenia post CAR T cell therapy: Etiology, potential mechanisms and perspective
Si, X., Gu, T., Liu, L., Huang, Y., Han, Y., Qian, P., & Huang, H. (2022) · Cancer Letters · doi:10.1016/j.canlet.2022.215920 · Cited by 35
Experts’ consensus on the definition and management of high risk multiple myeloma
Marcon, C., Simeon, V., Deias, P., Facchin, G., Corso, A., Derudas, D., Montefusco, V., Offidani, M., Petrucci, M. T., Zambello, R., et al. (2023) · Frontiers in Oncology · doi:10.3389/fonc.2022.1096852 · Cited by 37
“In Europe, CAR-T cells against BCMA antigen have been tested in the KarMMa and Cartitude trials in triple-class relapsed/refractory MM, showing promising results also in patients with high-risk cytogenetics (79, 80), that should be confirmed by real world data in larger groups of patients.”
MethodEmole, J., Lawal, O., Lupak, O., Dias, A., Shune, L. O., & Yusuf, K. K. (2022) · Cancer Medicine · doi:10.1002/cam4.4797 · Cited by 33
Jagannath, S., Joseph, N., Crivera, C., Kharat, A. A., Jackson, C. C., Valluri, S., Cost, P., Phelps, H., Slowik, R., Klein, T. M., et al. (2023) · Oncology and Therapy · doi:10.1007/s40487-023-00228-5 · Cited by 33
“2% bridging therapy, the average bridging therapy use in RRMM clinical trials for two CAR-T products [7, 18], increased the estimated per-patient average costs of CAR-T cilta-”
BackgroundInfluentialT-cell redirecting bispecific and trispecific antibodies in multiple myeloma beyond BCMA
van de Donk, N. W. C. J., O’Neill, C. A., de Ruijter, M. E. M., Verkleij, C. P. M., & Zweegman, S. (2023) · Current Opinion in Oncology · doi:10.1097/cco.0000000000000983 · Cited by 32
“The approved CAR T-cell products ide-cel [16] and cilta-cel [17] target BCMA, and also the T-cell redirecting BsAb teclistamab targets BCMA [13 && ].”
BackgroundMoreno-Cortes, E. F., Franco-Fuquen, P., García-Robledo, J. E., Forero-Forero, J. V., Booth, N. A., & Castro, J. E. (2023) · Frontiers in Oncology · doi:10.3389/fonc.2023.1200914 · Cited by 35
The Role of Cancer-Specific Target Antigens in CAR T Cell Therapy in Hematological Malignancies
Khan, T. H., Muhammad, N., Tarique, M., Usmani, D., Naz, H., & Sarode, A. Y. (2024) · Current Tissue Microenvironment Reports · doi:10.1007/s43152-024-00055-4 · Cited by 33
“The newly approved treatment for multiple myeloma is the inaugural CAR therapy that does not target CD19 but focuses on B-cell maturation antigen [62–65].”
Díez-Alonso, L., Falgàs, A., Arroyo-Ródenas, J., Romencín, P. A., Martínez, A., Gómez-Rosel, M., Blanco, B., Jiménez-Reinoso, A., Mayado, A., Pérez-Pons, A., et al. (2024) · Science Translational Medicine · doi:10.1126/scitranslmed.adg7962 · Cited by 31
“…CAR-T cells has shown unprecedented results with excellent safety profiles, leading to approval by the US Food and Drug Administration (FDA) and the European Medicines Agency (EMA) of two second-generation CAR-T cell products (idecabtagene vicleucel and ciltacabtagene autoleucel) ( 14 , 15 ).”
BackgroundTargeting the mevalonate or Wnt pathways to overcome CAR T-cell resistance in TP53-mutant AML cells
Mueller, J., Schimmer, R. R., Koch, C., Schneiter, F., Fullin, J., Lysenko, V., Pellegrino, C. E., Klemm, N., Russkamp, N. F., Myburgh, R., et al. (2024) · EMBO Molecular Medicine · doi:10.1038/s44321-024-00024-2 · Cited by 33
“…malignancies and multiple myeloma, and that could be an attractive option for TP53 -mutant AML/MDS as well (Berdeja et al, 2021; Davila et al, 2014; Kochenderfer et al, 2015; Lee et al, 2015a; Maude et al, 2014; Munshi et al, 2021; Neelapu et al, 2017; Schuster et al, 2019; Turtle et al, 2016a).”
BackgroundState of the Art in CAR-T Cell Therapy for Solid Tumors: Is There a Sweeter Future?
Amorós-Pérez, B., Rivas-Pardo, B., del Moral, M. G., Subiza, J. L., & Martı́nez-Naves, E. (2024) · Cells · doi:10.3390/cells13090725 · Cited by 34
“…therapies, idecabtagene vicleucel (ide-cel) and ciltacabtagene autoleucel (cilta-cel) have received approval for the treatment of adults with r/r MM after receiving three or more previous therapies, including an immunomodulatory agent, an anti-CD38 antibody, and a proteasome inhibitor [18,19].”
Method3D Multispheroid Assembly Strategies towards Tissue Engineering and Disease Modeling
Zhu, T., Hu, Y., Cui, H., & Cui, H. (2024) · Advanced Healthcare Materials · doi:10.1002/adhm.202400957 · Cited by 37
Tumor necrosis factor superfamily signaling: life and death in cancer
Ababneh, O. E., Nishizaki, D., Kato, S., & Kurzrock, R. (2024) · Cancer and Metastasis Reviews · doi:10.1007/s10555-024-10206-6 · Cited by 39
Eckmann, J., Fauti, T., Biehl, M., Zabaleta, A., Blanco, L., Lelios, I., Gottwald, S., Rae, R., Lechner, S., Bayer, C., et al. (2024) · Blood · doi:10.1182/blood.2024025987 · Cited by 35
Extramedullary Multiple Myeloma: Challenges and Opportunities
Ho, M., Paruzzo, L., Minehart, J. C., Nabar, N. R., Noll, J. H., Luo, T., Garfall, A. L., & Zanwar, S. (2025) · Current Oncology · doi:10.3390/curroncol32030182 · Cited by 39
“Ide-cel was approved based on a phase 2 KarMMa study, which demonstrated an overall response rate (ORR) of 73% and median PFS of 8.8 months [103].”
InfluentialCAR‐T‐OPENIA: Chimeric antigen receptor T‐cell therapy‐associated cytopenias
Taneja, A., & Jain, T. (2021) · eJHaem · doi:10.1002/jha2.350 · Cited by 33
Treating Multiple Myeloma in the Context of the Bone Marrow Microenvironment
Ho, M., Xiao, A. H., Yi, D., Zanwar, S., & Bianchi, G. (2022) · Current Oncology · doi:10.3390/curroncol29110705 · Cited by 34
Gagelmann, N., Ayuk, F. A., Klyuchnikov, E., Wolschke, C., Berger, S. C., & Kröger, N. M. (2023) · Haematologica · doi:10.3324/haematol.2022.282510 · Cited by 32
“Chimeric antigen receptor (CAR-) T cell therapy showed enormously promising results in patients with relapsed or refractory multiple myeloma,(1,2) leading to approval of the first 2 products by FDA/EMA.(3,4) Current responses seem to be comparable across CAR-T products and trials (both commercial and academic), with a…”
Novellis, D. D., Fontana, R., Giudice, V., Serio, B., & Selleri, C. (2022) · International Journal of Molecular Sciences · doi:10.3390/ijms24010645 · Cited by 34
“CAR-T cells can still be detected 12 months after infusion [118].”
BackgroundFugere, T., Baltz, A., Mukherjee, A., Gaddam, M., Varma, A., Veeraputhiran, M. K., & Sanchez, C. G. (2023) · Cancers · doi:10.3390/cancers15215149 · Cited by 37
“Idecabtagene vicleucel (Abecma) received FDA approval based on the result of the phase 2 KarMMA study with long-term efficacy and safety data reporting a 4% rate of HLH/MAS in this population [42].”
BackgroundCAR-T cell combination therapies in hematologic malignancies
Zhou, D., Zhu, X., & Xiao, Y. Q. (2024) · Experimental Hematology and Oncology · doi:10.1186/s40164-024-00536-0 · Cited by 39
Bachiller, M., Barceló-Genestar, N., Rodríguez-García, A., Alserawan, L., Dobaño‐López, C., Giménez-Alejandre, M., Castellsagué, J., Colell, S., Otero-Mateo, M., Antoñana-Vildosola, A., et al. (2024) · Molecular Therapy · doi:10.1016/j.ymthe.2024.11.028 · Cited by 35
Jurgens, E. M., Firestone, R., Chaudhari, J., Hosszu, K., Devlin, S. M., Shah, U. A., Landa, J., McAvoy, D. P., Lesokhin, A. M., Korde, N., et al. (2024) · Journal of Clinical Oncology · doi:10.1200/jco-24-01785 · Cited by 36
Allogeneic off-the-shelf CAR T-cell therapy for relapsed or refractory B-cell malignancies
Shahid, S., Prockop, S. E., Flynn, G. C., Mauguen, A., White, C., Bieler, J., McAvoy, D. P., Hosszu, K., Cancio, M., Jakubowski, A. A., et al. (2025) · Blood Advances · doi:10.1182/bloodadvances.2024015157 · Cited by 34
Tracing the development of CAR-T cell design: from concept to next-generation platforms
Alsaieedi, A., & Zaher, K. A. (2025) · Frontiers in Immunology · doi:10.3389/fimmu.2025.1615212 · Cited by 49
“Thereafter, more CD19-redirected CAR-T cell therapies were also approved by the FDA, including Tecartus (brexucabtagene autoleucel), Breyanzi (lisocabtagene maraleucel), Carvykti (ciltacabtagene, autoleucel), and Abecma (idecabtagene vicleucel) (9, 19).”
High-risk multiple myeloma: how to treat at diagnosis and relapse?
Mateos, M., Puertas, B., & González‐Calle, V. (2021) · Hematology · doi:10.1182/hematology.2021000229 · Cited by 33
Recent advances of nanodrug delivery system in the treatment of hematologic malignancies
Ye, Q.-L., Lin, Y. H., Li, R., Wang, H., & Dong, C. (2022) · Seminars in Cancer Biology · doi:10.1016/j.semcancer.2022.03.016 · Cited by 33
Self-citationQu, X., An, G., Sui, W., Wang, T., Zhang, X., Yang, J., Zhang, Y., Zhang, L., Zhu, D., Huang, J., et al. (2022) · Journal for ImmunoTherapy of Cancer · doi:10.1136/jitc-2022-005145 · Cited by 33
Efficace, F., Cannella, L., Sparano, F., Giesinger, J. M., Vignetti, M., Baron, F., Bruera, E. D., Luppi, M., & Platzbecker, U. (2022) · HemaSphere · doi:10.1097/hs9.0000000000000802 · Cited by 34
Drougkas, K., Karampinos, K. I., Karavolias, I., Koumprentziotis, I., Ploumaki, I., Triantafyllou, E., Trontzas, I. P., & Kotteas, E. A. (2022) · Journal of Cancer Research and Clinical Oncology · doi:10.1007/s00432-022-04547-4 · Cited by 30
Zinzi, A., Gaio, M., Liguori, V., Cagnotta, C., Paolino, D., Paolisso, G., Castaldo, G., Nicoletti, G. F., Rossi, F., Capuano, A., et al. (2023) · Pharmacological Research · doi:10.1016/j.phrs.2023.106742 · Cited by 33
Akhtar, O. S., Sheeba, B. A., Azad, F., Alessi, L., Hansen, D. K., Alsina, M., Baz, R., Shain, K. H., Grajales-Cruz, A. F., Puglianini, O. A. C., et al. (2023) · Journal of Geriatric Oncology · doi:10.1016/j.jgo.2023.101628 · Cited by 31
Ferment, B., Lambert, J., Caillot, D., et al. (2024) · British Journal of Haematology · doi:10.1111/bjh.19505 · Cited by 31
Self-citationPhase 1 study of CAR-37 T cells in patients with relapsed or refractory CD37+ lymphoid malignancies
Frigault, M. J., Graham, C., Berger, T. R., Ritchey, J., Horick, N., El-Jawahri, A. R., Scarfò, I., Schmidts, A., Haradhvala, N. J., Wehrli, M., et al. (2024) · Blood · doi:10.1182/blood.2024024104 · Cited by 37
Self-citationCosta, B. A., Flynn, J. R., Nishimura, N., Devlin, S. M., Farzana, T., Rajeeve, S., Chung, D. J., Landau, H. J., Lahoud, O. B., Scordo, M., et al. (2024) · Blood Cancer Journal · doi:10.1038/s41408-024-01048-0 · Cited by 34
Ramberger, E., Sapozhnikova, V., Ng, Y. L. D., Dolnik, A., Ziehm, M., Popp, O., Sträng, E., Kull, M., Grünschläger, F., Krüger, J., et al. (2024) · Nature Cancer · doi:10.1038/s43018-024-00784-3 · Cited by 47
“Immunotherapies such as CAR-T cells and bispecific antibodies targeting BCMA and GPCR5D are approved and highly effective treatments for MM 48,49 .”
BackgroundSelf-citationYang, Y., Peng, H., Wang, J., & Li, F. (2024) · Experimental Hematology and Oncology · doi:10.1186/s40164-024-00573-9 · Cited by 37
Recent advances in universal chimeric antigen receptor T cell therapy
Jiang, N., Yang, Z., Miao, H., Xing, S., Wang, S., & Li, N. (2025) · Journal of Hematology & Oncology · doi:10.1186/s13045-025-01737-8 · Cited by 41
“Numerous clinical trials have demonstrated that CAR T cell therapy can induce deep and durable remissions[1–5].”
Arias-Pinilla, G. A., & Modjtahedi, H. (2021) · Cancers · doi:10.3390/cancers13081781 · Cited by 32
“More recently, the B‐cell maturation antigen (BCMA)‐directed genetically modified autologous CAR T‐cell therapy idecabtagene vicleucel has been approved for relapsed or refractory multiple myeloma [198].”
BackgroundClinical translation of immunomodulatory therapeutics
Nash, A., Aghlara-Fotovat, S., Hernández, A., Scull, C. M., & Omid Veiseh, A. (2021) · Advanced Drug Delivery Reviews · doi:10.1016/j.addr.2021.113896 · Cited by 31
Nanobody-armed T cells endow CAR-T cells with cytotoxicity against lymphoma cells
Wang, H., Wang, L., Li, Y., Li, G., Zhang, X., Jiang, D., Zhang, Y.-T. Y., Liu, L., Chu, Y., & Xu, G. (2021) · Cancer Cell International · doi:10.1186/s12935-021-02151-z · Cited by 31
Buechner, J., Caruana, I., Künkele, A., Rives, S., Vettenranta, K. K., Bader, P., Peters, C., Baruchel, A., & Calkoen, F. (2022) · Frontiers in Pediatrics · doi:10.3389/fped.2021.784024 · Cited by 32
Asherie, N., Kfir‐Erenfeld, S., Avni, B. R., Assayag, M., Dubnikov, T., Zalcman, N., Lebel, E., Zimran, E., Shaulov, A., Pick, M., et al. (2022) · Haematologica · doi:10.3324/haematol.2022.281628 · Cited by 31
“Time since diagnosis in months, median (range) 55 (8-241) 42 (20-123) 78 (44-241) 43 (8-104)”
Immunotherapy approaches for hematological cancers
Lanier, O. L., Pérez‐Herrero, E., Andrea, A. P. D. ’., Bahrami, K., Lee, E. Y. P., Ward, D. M., Ayala-Suárez, N., Rodríguez-Méndez, S. M., & Peppas, N. A. (2022) · iScience · doi:10.1016/j.isci.2022.105326 · Cited by 36
“This is the first FDA-approved CAR T cell therapy for multiple myeloma (Munshi et al., 2021; U.S. Food and Drug Administration (FDA), 2021a).”
Rana, P. S., Soler, D. C., Kort, J., & Driscoll, J. J. (2022) · Frontiers in Cell and Developmental Biology · doi:10.3389/fcell.2022.1059715 · Cited by 34
“CAR T cells have been shown high response rates for RRMM patients (Berdeja et al., 2021; Munshi et al., 2021) (Fig.”
BackgroundMody, H. R., Ogasawara, K., Zhu, X., Miles, D., Shastri, P. N., Gokemeijer, J., Liao, M. Z., Kasichayanula, S., Yang, T., Chemuturi, N. V., et al. (2023) · Clinical Pharmacology & Therapeutics · doi:10.1002/cpt.2986 · Cited by 34
“Idecabtagene vicleucel (ide- cel) exposure increased with increasing dose within the evaluated target dose range of 150– 450 × 10(6) CAR+ T cells, however, the high interindividual variability resulted in substantial overlap of ide- cel exposure across the target dose levels.(34,35) A positive dose- efficacy/safety re…”
BackgroundMethodTargeted immunotherapy: harnessing the immune system to battle multiple myeloma
Xu, L., Wen, C., Xia, J., Zhang, H., Liang, Y., & Xu, X. G. (2024) · Cell Death Discovery · doi:10.1038/s41420-024-01818-6 · Cited by 32
CAR-T cells for treating systemic lupus erythematosus: A promising emerging therapy
Guffroy, A., Jacquel, L., Guffroy, B., & Martin, T. (2024) · Joint Bone Spine · doi:10.1016/j.jbspin.2024.105702 · Cited by 31
Delforge, M., Patel, K., Eliason, L., Dhanda, D., Shi, L., Guo, S., Marshall, T. S., Arnulf, B., Cavo, M., Nooka, A., et al. (2024) · The Lancet Haematology · doi:10.1016/s2352-3026(24)00005-x · Cited by 31
Self-citationAdoptive Cell Therapy for Solid Tumors: Current Status in Melanoma and Next-Generation Therapies
Haanen, J. B. A. G., Los, C., Phan, G. Q., & Warner, A. B. (2024) · American Society of Clinical Oncology Educational Book · doi:10.1200/edbk_431608 · Cited by 31
PET/CT in the Evaluation of CAR-T Cell Immunotherapy in Hematological Malignancies
Singh, S. B., Bhandari, S., Siwakoti, S., Kumar, M., Singh, R., Bhusal, S., Sharma, K., Bhandari, S., & Khanal, K. (2024) · Molecular Imaging · doi:10.1177/15353508241257924 · Cited by 34
New horizons in our understanding of precursor multiple myeloma and early interception
dos Santos, D. M. C., Toenges, R., Bertamini, L., Alberge, J.-B., & Ghobrial, I. M. (2024) · Nature reviews. Cancer · doi:10.1038/s41568-024-00755-x · Cited by 34
“These findings raise questions about whether the early application of T cell-redirecting therapies might lead to long-lasting remissions or even a cure.”
Overcoming solid-tumor barriers: armored CAR-T cell therapy
Kwon, N., & Chen, Y. Y. (2025) · Trends in cancer · doi:10.1016/j.trecan.2025.08.009 · Cited by 33
Strengthening the CAR‐T cell therapeutic application using CRISPR/Cas9 technology
Nezhad, M. S., Yazdanifar, M., Abdollahpour‐Alitappeh, M., Sattari, A., Seifalian, A. M., & Bagheri, N. (2021) · Biotechnology and Bioengineering · doi:10.1002/bit.27882 · Cited by 30
“(I) Idecabtagene vicleucel (Abecma) is an autologous B‐cell maturation antigen (BCMA) CAR‐T cell designed for patients with relapsed or refractory (R/R) myeloma (Munshi et al., 2021).”
BackgroundEmerging therapies for relapsed/refractory multiple myeloma: CAR-T and beyond
Su, C. T., & Ye, J. C. (2021) · Journal of Hematology & Oncology · doi:10.1186/s13045-021-01109-y · Cited by 30
“Most recently, attesting to the vibrancy of ongoing myeloma research, the firstin-class B-cell maturation antigen (BCMA)-targeted antibody–drug conjugate (belantamab mafodotin) was approved in August 2020 [5], and BCMA-targeted CAR-T cell therapy (idecabtagene vicleucel) in March 2021 [6].”
BackgroundChimeric antigen receptor (CAR) T-cell therapy for multiple myeloma
Choi, T., & Kang, Y. (2021) · Pharmacology & Therapeutics · doi:10.1016/j.pharmthera.2021.108007 · Cited by 30
Cancer-Homing CAR-T Cells and Endogenous Immune Population Dynamics
Guerra, E., Pietro, R. D., Basile, M., Trerotola, M., & Alberti, S. (2021) · International Journal of Molecular Sciences · doi:10.3390/ijms23010405 · Cited by 30
“FDA-approved CAR-T cell therapies now include CTL019 (Kymriah) [52], KTE-C19 (Yescarta) [53], JCAR017 (Breyanzi) [54], KTE-X19 (Tecartus) [55], and bb2121 (Abecma) [56].”
Development of HIV-Resistant CAR T Cells by CRISPR/Cas-Mediated CAR Integration into the CCR5 Locus
Rothemejer, F. H., Lauritsen, N. P., Juhl, A. K., Schleimann, M. H., König, S., Søgaard, O. S., Bak, R. O., & Tolstrup, M. (2023) · Viruses · doi:10.3390/v15010202 · Cited by 31
Moreau, P., van de Donk, N. W. C. J., Delforge, M., Einsele, H., Stefano, V. D., Perrot, A., Besemer, B., Pawlyn, C., Karlin, L., Manier, S., et al. (2023) · Advances in Therapy · doi:10.1007/s12325-023-02480-7 · Cited by 31
Self-citation
Metadata
- Authors
- Munshi, N. C., Anderson, L. D., Shah, N., Madduri, D., Berdeja, J., Lonial, S., Raje, N., Lin, Y., Siegel, D., Oriol, A., Moreau, P., Yakoub-Agha, I., Delforge, M., Cavo, M., Einsele, H., Goldschmidt, H., Weisel, K., Rambaldi, A., Reece, D., Petrocca, F., Massaro, M., Connarn, J. N., Kaiser, S., Patel, P., Huang, L., Campbell, T. B., Hege, K., & San-Miguel, J.
- Affiliations
- Harvard University (US)
- Mayo Clinic (US)
- Hackensack University Medical Center (US)
- From the Jerome Lipper Multiple Myeloma Center, Dana–Farber Cancer Institute (N.C.M.), the Veterans Affairs Boston Healthcare System, Harvard Medical School (N.C.M.), and Massachusetts General Hospital (N.R.), Boston, and bluebird bio, Cambridge (F.P., M.M.) — all in Massachusetts; Simmons Comprehensive Cancer Center, University of Texas Southwestern Medical Center, Dallas (L.D.A.); the University of California, San Francisco, San Francisco (N.S.); Icahn School of Medicine at Mount Sinai, New York ...
- ORCID
- Munshi, Nikhil C.
- Anderson, Larry D.
- Shah, Nina
- Madduri, Deepu
- Berdeja, Jesús
- Lonial, Sagar
- Raje, Noopur
- Lin, Yi
- Siegel, David
- Oriol, Albert
- Moreau, Philippe
- Yakoub-Agha, Ibrahim
- Delforge, Michel
- Einsele, Hermann
- Goldschmidt, Hartmut
- Weisel, Katja
- Rambaldi, Alessandro
- Reece, Donna
- Petrocca, Fabio
- Connarn, Jamie N.
- Kaiser, Shari
- Patel, Payal
- Huang, Liping
- Campbell, Timothy B.
- Hege, Kristen
- Venue
- New England Journal of Medicine
- Publisher
- Massachusetts Medical Society
- Published
- 2021-02-25
- Volume
- 384
- Issue
- 8
- Pages
- 705-716
- ISSN
- 0028-4793 (ISSN-L)
- 1533-4406
- OpenAlex
- W3133229959
- Semantic Scholar
- fd96e2f87dff7d1153a17b78b56fbbab69cb714e
- Cited by
- 2,560
- References
- 17
- Citations by year
- 2026: 411 · 2025: 486 · 2024: 540 · 2023: 493 · 2022: 436 · 2021: 186
- FWCI
- 150.68
- Type
- journal article
- Language
- en
- Open access
- bronze
- doi.org
- Locations
- New England Journal of Medicine (publishedVersion)
- PubMed (publishedVersion)
- HAL (submittedVersion)
- Archivio istituzionale della ricerca (Alma Mater Studiorum Università di Bologna) (submittedVersion, other-oa)
- Lirias (KU Leuven) (submittedVersion)
- Funders
- Bristol-Myers Squibb
- Topics
- Health Sciences › Medicine › Oncology › CAR-T cell therapy research
- Health Sciences › Medicine › Hematology › Multiple Myeloma Research and Treatments
- Life Sciences › Biochemistry, Genetics and Molecular Biology › Molecular Biology › Protein Degradation and Inhibitors
- Keywords
- idecabtagene vicleucel, CAR T-cell therapy, relapsed/refractory multiple myeloma, BCMA, minimal residual disease, cytokine release syndrome, neurotoxicity, CAR T cell persistence, progression-free survival, complete response, neutropenia, anemia, thrombocytopenia, chimeric antigen receptor T cells
- MeSH terms
- Receptors, Chimeric Antigen, Progression-Free Survival, Cytokine Release Syndrome, Adult, Aged, Female, Hematologic Diseases, Humans, Male, Middle Aged, Multiple Myeloma, Recurrence, Biomarkers, Immunotherapy, Adoptive, Drug Resistance, Neoplasm
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
A language model drew the claims from the paper on 2026-10-11, under version 3 of the claim definition (model deepseek-v4.1-flash, prompt extract-v3).
A second model labelled each claim on 2026-10-11 (model jev-1.13-20260917, definition revision gold-guideline-v0.2).
Cited sources are checked with a language model’s help (gpt-6-sol).
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
